Biogen
BIIB
656 hedge funds and large institutions have $53B invested in Biogen in 2013 Q3 according to their latest regulatory filings, with 73 funds opening new positions, 227 increasing their positions, 253 reducing their positions, and 54 closing their positions.
35% more first-time investments, than exits
New positions opened: 73 | Existing positions closed: 54
12% more capital invested
Capital invested by funds: $47.5B → $53B (+$5.47B)
2% more funds holding
Funds holding: 646 → 656 (+10)
10% less call options, than puts
Call options by funds: $619M | Put options by funds: $689M
10% less repeat investments, than reductions
Existing positions increased: 227 | Existing positions reduced: 253
17% less funds holding in top 10
Funds holding in top 10: 29 → 24 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$473M |
| 2 |
O
OppenheimerFunds
New York
|
+$371M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$179M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$108M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$104M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
Marsico Capital Management
Denver,
Colorado
|
-$251M |
| 2 |
JP Morgan Chase
New York
|
-$226M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$151M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$138M |
| 5 |
Winslow Capital Management
Minneapolis,
Minnesota
|
-$118M |
BIIB Hedge Fund Activity: Q3 2013 in Review
656 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q3 2013, worth a combined $53B — up 12% from $47.5B a quarter earlier.
Buyers outnumbered sellers: 73 funds opened new BIIB positions and 54 closed out — a net gain of 19 holders — while 227 added to existing stakes and 253 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $473M. The largest seller was Marsico Capital Management, cutting an estimated $251M.
- 656 institutional investors held Biogen (BIIB) as of Q3 2013, up from 646 in Q2 2013.
- Funds reported $53B of Biogen stock for Q3 2013, up 12% quarter-over-quarter.
- 73 funds opened new Biogen positions in Q3 2013 and 54 closed out, a net change of +19 holders.
- The largest Biogen buyer in Q3 2013 was Fidelity Investments, an estimated $473M added.
- The largest Biogen seller in Q3 2013 was Marsico Capital Management, an estimated $251M sold.
Based on aggregated 13F filings for Q3 2013.